Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis

Treatment (Symptomatic & Disease-Modifying)

The symptomatic segment in the oculopharyngeal muscular dystrophy market is estimated to gain the largest revenue share of about 59% in the year 2036. The segment growth can be attributed to the burgeoning geriatric population which makes the populace more susceptible to oculopharyngeal muscular dystrophy.According to surveys by various firms and organizations this disorder has been reported approximately in 29 countries. Additionally, the high cost and risk of side effects of surgery and disease-modifying treatments has led to the rise of the segment as symptomatic treatment which mostly consists of therapies like the wide range of motion stretching exercises, braces which add mobility and function by providing support for weakened muscles, sleep apnea device that helps improve oxygen delivery during the night.

End-User (Hospitals, Diagnostic Centers, Clinics)

The hospital segment in the oculopharyngeal muscular dystrophy market is estimated to gain the largest revenue share of about 42% in the year 2036. The availability of hospitals in every region of the world alongside the presence of advanced therapeutic medicinal products for the treatment of oculopharyngeal muscular dystrophy is expected to drive the segment growth. To make reference, as of 2021, there are reportedly around 167,000 hospitals in the world. Asia has over 100,000 hospitals alone. Additionally, the rising inclination towards hospitals for receiving treatment by the population owning to the easy accessibility of trained medical staff and professionals among other factors attributed to the segment’s market growth.

Our in-depth analysis of the global market includes the following segments: